Picard Medical / SynCardia Showcases Leadership in Total Artificial Heart Therapy at Technology and Heart Failure Therapeutics Conference

Core Insights - Picard Medical, Inc. is advancing its leadership in artificial heart technology with the SynCardia Total Artificial Heart and the next-generation Emperor system, focusing on not just survival but also quality of life and transplant eligibility [1][2]. Company Overview - Picard Medical, Inc. is the parent company of SynCardia Systems, LLC, which is the only provider of commercially available total artificial heart technology for end-stage heart failure patients [5]. - The SynCardia Total Artificial Heart (STAH) is the first artificial heart approved by both the U.S. FDA and Health Canada, with over 2,100 implants performed globally [5]. Conference Participation - Dr. Andre Simon, Vice President of Clinical Affairs, will present at the Technology and Heart Failure Therapeutics (THT) 2026 conference, showcasing the company's commitment to innovation and education in heart failure therapies [1][2]. - The conference will feature discussions on emerging technologies and clinical data aimed at improving patient outcomes in heart failure management [4]. Presentation Highlights - Dr. Simon's presentations will cover: - The Emperor system's early laboratory and preclinical data, emphasizing its design for improved patient mobility and independence [2]. - Future priorities in total artificial heart therapy, including earlier intervention and organ recovery [3]. - Updated registry analyses demonstrating that outcomes with the STAH extend beyond survival to include functional improvement and quality of life enhancements [3].